South Korea Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The south korea cardiovascular devices market size was valued at USD 1.29 billion in 2025 and estimated to grow from USD 1.39 billion in 2026 to reach USD 1.99 billion by 2031, at a CAGR of 7.47% during the forecast period (2026-2031). This report is Segmented by Device Type (Diagnostic & Monitoring Devices Including ECG Systems, Remote Cardiac Monitor, and More; Therapeutic & Surgical Devices Including Coronary Stents, Catheters, and More), Application (Coronary Artery Disease, Arrhythmia, and More), End User (Hospitals, Home Care Settings, Others). The Market Forecasts are Provided in Terms of Value (USD).

South Korea Cardiovascular Devices Market Trends and Insights

Demographic Shift to a Super-Aged Society

South Korea already counts 17.5% of its citizens at least 65 years old in 2024, and official projections place seniors at nearly 35% by 2045. Cardiovascular procedure volumes are rising 12% each year, with octogenarians representing 22% of all percutaneous coronary interventions in 2024. Device makers have responded with geriatric-oriented designs that offer enhanced durability, simplified user interfaces, and embedded remote-monitoring chips. Hospitals are seeing longer lengths of stay and growing demand for low-profile catheters and smaller valve sizes that fit frail anatomies. These trends reinforce multiyear visibility for device replacement demand and recurring consumables.

NHI Reimbursement Expansion for Transcatheter Therapies

In April 2024 the National Health Insurance scheme extended coverage to transcatheter aortic valve replacement for intermediate-risk patients, opening treatment to an additional 4,200 cases annually. TAVR volumes jumped 37% quarter-over-quarter in Q2 2024, with Edwards Lifesciences and Medtronic jointly serving 78% of the expanded pool. The reimbursement upgrade also included drug-coated balloons for peripheral artery disease and next-generation left-atrial-appendage closure systems, giving suppliers multiple avenues for growth. Analysts at the Health Insurance Review & Assessment Service estimate a 22% increase in overall cardiovascular procedure volumes and an 8% reduction in total care costs tied to fewer surgical complications and shorter hospital stays.

Stringent MFDS Approval Pathway for Class-III Heart Valves

Enhanced MFDS regulations implemented in January 2024 require durability testing of 600 million cycles and thorough thrombogenicity profiling, extending approval timelines to 22 months compared with 11 months in the United States. Compliance expenses rose 35%, prompting three domestic valve developers to prioritize Southeast-Asian launches where requirements are lighter. Smaller firms face liquidity strain, while established players adjust by front-loading bench testing and investing in local clinical trials to shorten review cycles. Hospitals experience longer technology refresh lags, delaying patient access to latest-generation valves.

Other drivers and restraints analyzed in the detailed report include:

• Rapid Uptake of High-End Imaging Modalities
• Cardiovascular AI Software Adoption
• Workforce Shortage of Interventional Cardiologists in Provincial Areas

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic and surgical devices held a 53.74% revenue slice of the South Korea cardiovascular devices market in 2025, buoyed by high drug-eluting-stent penetration where DES comprised 87% of placements. The cardiac-rhythm-management niche is gaining renewed momentum after NHI endorsed leadless pacemakers and subcutaneous ICDs, sparking double-digit unit growth. Structural-heart interventions now absorb an expanding capital budget as TAVR case counts jumped 37% year-over-year following intermediate-risk coverage.

Diagnostic and monitoring devices, though smaller, are projected to show an 7.72% CAGR, outpacing the broader South Korea cardiovascular devices market. Remote cardiac monitors dominate momentum thanks to reimbursement for post-discharge surveillance paired with AI arrhythmia detection, a combination that cut heart-failure readmissions 42% in a 2024 multi-center trial. Echo systems sit atop diagnostic spending, with 3D strain imaging triggering accelerated replacement cycles, while optical fractional-flow-reserve systems gain share by slashing procedural time in cath labs.

Complete Report Scope:

• By Device
  • Diagnostic & Monitoring Devices
    • ECG Systems
    • Remote Cardiac Monitor
    • Cardiac MRI
    • Cardiac CT
    • Echocardiography / Ultrasound
    • Fractional Flow Reserve (FFR) Systems
  • Therapeutic & Surgical Devices
    • Coronary Stents
      • Drug-Eluting Stents
      • Bare-Metal Stents
      • Bioresorbable Stents
    • Catheters
      • PTCA Balloon Catheters
      • IVUS/OCT Catheters
    • Cardiac Rhythm Management
      • Pacemakers
      • Implantable Cardioverter Defibrillators
      • Cardiac Resynchronization Therapy Devices
    • Heart Valves
      • TAVR/TAVI
      • Mechanical Valves
      • Tissue/Bioprosthetic Valves
    • Ventricular Assist Devices
    • Artificial Hearts
    • Grafts & Patches
    • Other Cardiovascular Surgical Devices
• By Indication
  • Coronary Artery Disease
  • Arrhythmia
  • Heart Failure
  • Valvular Heart Disease
• By End User
  • Hospitals
  • Home care Settings
  • Others

List of Companies Covered in this Report:

• Abbott Laboratories
• Boston Scientific
• Terumo Corp.
• Edward Lifesciences
• Koninklijke Philips
• GE Healthcare
• Siemens Healthineers
• BIOTRONIK
• Johnson & Johnson (Biosense Webster & Cordis Korea)
• MicroPort Scientific Corp.
• Osstem Cardiotech Co., Ltd
• Genoss Co., Ltd
• Nipro Corp.
• Lepu Medical
• Meril Life Sciences
• Fukuda Denshi Co., Ltd
• Nihon Kohden

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support